These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 7295080

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
    Asaba H, Alvestrand A, Bergström J, Fürst P, Yahiel V.
    Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
    [Abstract] [Full Text] [Related]

  • 3. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H, Alvestrand A, Fürst P, Bergström J.
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Uremic middle molecules exist and are biologically active.
    Bergström J, Fürst P, Zimmerman L.
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract] [Full Text] [Related]

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 9. Characterization of middle molecule compounds.
    Zimmerman L, Jörnvall H, Bergström J, Fürst P, Sjövall J.
    Artif Organs; 1981 Nov; 4 Suppl():33-6. PubMed ID: 7295092
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Chemical analytic approaches to the definition of uremic toxins.
    Furst P, Bergstrom J, Gordon A, Zimmermann L.
    Ateneo Parmense Acta Biomed; 1975 Nov; 46(5):307-16. PubMed ID: 1232992
    [Abstract] [Full Text] [Related]

  • 14. Transport of uremic toxins through conventional hemodialysis membranes.
    Jörstad S, Smeby LC, Wideröe TE, Berg KJ.
    Clin Nephrol; 1979 Oct; 12(4):168-73. PubMed ID: 509791
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Toxicity of middle molecules: clinical evaluation using a selective filtration artificial kidney.
    Jörstad S, Smeby LC, Wideröe TE.
    Artif Organs; 1981 Oct; 4 Suppl():98-103. PubMed ID: 7295103
    [Abstract] [Full Text] [Related]

  • 17. In vitro cytotoxic properties of plasma fractions from uremic patients.
    Delaporte C, Gros F, Jonsson C, Bergström J.
    Artif Organs; 1981 Oct; 4 Suppl():68-70. PubMed ID: 7295099
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L, Dall'taglio P, Buzio C.
    Clin Nephrol; 1975 Oct; 3(3):82-93. PubMed ID: 1139803
    [Abstract] [Full Text] [Related]

  • 20. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L, Petrović J, Potić J.
    Acta Med Iugosl; 1990 Oct; 44(2):117-28. PubMed ID: 2162129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.